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A novel diagnostic immunoassay testing procedure for hepatitis B virus core antibody (anti-HBc) using
homogeneous purified full-length hepatitis B virus core antigen (HBcAg) capsids obtained from Escherichia coli
was compared with Abbott Architect anti-HBc chemiluminescent microparticle immunoassay (CMIA; indirect
method) against a library of specimens. A monoclonal anti-HBc neutralization confirmatory assay was then
used to determine the degree of discordance between specimens. The new assay was found to be superior in
both sensitivity and specificity.
Antibodies (anti-HBc) to hepatitis B virus (HBV) core an-
tigen (HBcAg) are present in current and past HBV infections.
Anti-HBc antibodies represent a long-term serological marker
of HBV infection, initially appearing during the acute phase of
the infection and generally persisting thereafter (16). Thus, as
anti-HBc is a universal marker of HBV infection, routine
blood donor screening for anti-HBc has been implemented in
some countries with low endemicity. It is a cost-effective
method of screening. Such screening procedures have resulted
in a decrease in the risk of posttransfusion HBV infections
(12). In some individuals, the only serological marker of HBV
infection is the presence of anti-HBc antibodies (10, 24), and
thus detection of “anti-HBcAg alone” could reflect unrecog-
nized “occult” HBV infection and physicians should consider
investigating such patients with HBV molecular tests (21).
Additionally, isolated anti-HBc can be used as a marker to
assess the risk of HBV reactivation in patients undergoing
therapy that could result in immunosuppression or patients
who are HIV positive (17) or hepatitis C virus (HCV) positive
(25).
With these uses in mind, having a more efficient and reliable
assay for anti-HBc is desirable. Most current commercially
available anti-HBc assays have poor sensitivity or specificity (2,
19) and can be attributed to the inferior performance of the
competitive immunoassay, especially for detecting low-titer anti-
HBc-reactive samples. False-positive reactivity can partially be
attributed to unspecific activation of premature B lymphocytes
causing the production of IgM, IgA, or IgM-related molecules
without previous exposure to HBV (18, 19). The specificity of
competitive assays for anti-HBc can be significantly improved
by addition of mild reducing agents, but such modified proce-
dures often lead to the loss of sensitivity, particularly for IgM
anti-HBc (23). In this study, a novel immunoassay for anti-HBc
based on the double-antigen sandwich enzyme-linked immu-
nosorbent assay (ELISA) method is compared with a commer-
cial anti-HBc assay, the Architect chemiluminescent micropar-
ticle immunoassay (CMIA).
MATERIALS AND METHODS
Expression and purification of full-length rHBcAg in E. coli. Two full-length
HBcAg genes were obtained by chemosynthesis: AB090269 (genotype D, named
CpD) and AB014368 (genotype C, named CpC). The rare arginine codes in
Escherichia coli (AGA and AGG) located in the HBcAg gene were changed to
CGT. The two fragments were inserted into the pTO-T7 vector by NdeI and
HindIII restriction sites and transformed into Escherichia coli BL21 cells for
HBcAg expression. The transformant was cultured in LB medium at 37°C for 5 h
and then further incubated for 8 h in the presence of 1 mM IPTG (isopropyl
-D-thiogalactoside). Cells were harvested and then centrifuged at 10,000 g for
10 min, after which they were lysed by sonication. HBcAg in the supernatant was
precipitated with 23% ammonium sulfate and collected by centrifugation. The
precipitated fraction was dissolved with 4 M urea buffer (20 mM Tris-HCl, pH
8.0, containing 4 M urea, and 20 mM dithiothreitol [DTT]) and purified in a Q
FF column and phenyl high-performance (HP) column (Amersham GE Health,
Uppsala, Sweden) with the AKTA system (GE Health, Uppsala, Sweden). The
purity and identity of the protein were analyzed by SDS-PAGE and Western
blotting.
In vitro HBc capsid assembly. HBcAg expressed in E. coli accumulates in a
particulate state referred to herein as HBcAg capsids. The precipitated fraction
of the salting-out process was dissolved in a buffer containing urea and DTT to
dissociate the particles which might entrap turbid proteins and nucleic acids and
hence interfere with the immunoassay. The purified HBcAg was first dialyzed
against 20 mM Tris-HCl (pH 8.0), containing 4 M urea and 20 mM DTT to
remove NaCl; and then against 20 mM Tris-HCl (pH 8.0), containing 20 mM
DTT to remove urea; and finally against 20 mM sodium phosphate (pH 6.0),
containing 300 mM NaCl to remove DTT and trigger spontaneous assembly.
These processes were performed using the Cross-Flow filtration systems (Am-
ersham GE Health, Uppsala, Sweden). The homogeneity of the assembled re-
combinant HBc (rHBc) capsids was then identified by transmission electron
microcopy (JEM 2100; JEOL, Tokyo, Japan).
The double-antigen sandwich immunoassay for anti-HBc. The purified CpD
protein was conjugated with horseradish peroxidase (HRP) by the NaIO4 oxi-
dation method. The conjugate was purified by gel filtration chromatography on
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a Superdex 200HR column. The purified CpD-HRP conjugate was mixed with an
equal volume of glycerin and stored at 20°C.
Microtiter wells (Yixinmei, Xiamen, China) were coated with 100 l of a
mixture of 4 g/ml CpC solution (diluted in 50 mM Tris-HCl, pH 8.0) overnight.
Thereafter, the wells were washed twice with phosphate-buffered saline (PBS;
pH 7.4), followed by incubation with a blocking reagent (10% sucrose, 1%
casein-Na, and 2% bovine serum albumin [BSA], in PBS, pH 7.4) at 37°C for 2 h.
After removing the blocking solution, the wells were vacuum dried and stored at
4°C. A 50-l specimen aliquot was mixed with 50 l of assay buffer and then
added to each well and incubated for 30 min at 37°C. After incubation, the wells
were washed with a wash buffer (0.05% Tween 20 in PBS, pH 7.4). A 100-l
aliquot of CpD-HRP solution was added to each well and incubated for 30 min
at 37°C. After rinsing 5 times with the wash buffer, 100 l of tetramethylbenzi-
dine (TMB) substrate solution (Wantai, Beijing, China) was added, and the
mixture was then incubated for 15 min at 37°C. The absorbance was measured at
450 nm and 620 nm using a microplate reader (Tecan, Switzerland).
Determination of cutoff value. A total of 2,656 serum samples from healthy
blood donors collected from Xiamen Blood Centre were measured to charac-
terize the optical density at 450 nm (OD450) with reference readings taken at 620
nm (data not shown), and the cutoff value for the sandwich ELISA was set as the
mean 3 standard deviations (SDs), equal to a negative control well 0.12. The
figure of 3 SDs was an arbitrary one which would cover 99.7% of the distribution.
Anti-HBc neutralization confirmatory assay. A neutralization confirmatory
assay based on an indirect chemiluminescent enzyme immunoassay (CLEIA) was
used as the gold standard to determine the true status of a specimen for which
a discrepancy from a different anti-HBc assay was found. In this assay, the
CpC-coated wells were incubated with an anti-HBc monoclonal antibody (MAb)
(16D5; 20 g/well), anti-HB e antigen (anti-HBe) MAb (10D8; 20 g/well), an
unrelated antibody (anti-human papillomavirus type 18 [anti-HPV18] L1; 20
g/well), and a blank assay buffer (20% fetal bovine serum in PBS) in parallel at
37°C for 30 min. The wells were then washed once, and 30-l samples were
added to each well filled with 70 l of assay buffer and incubated at 37°C for 30
min. After five washes, a 100-l aliquot of HRP-conjugated goat anti-human IgG
solution was added to each well and incubated for 30 min at 37°C. The wells were
then washed 5 more times, 100 l of substrate solution (Luminol) was added for
reaction, and the result was read by an Orin II microplate chemiluminescence
reader (Berthod, DE). The neutralization rate was calculated as the percentage
of the decreased relative light unit (RLU) value of the anti-HBc MAb-blocked
well compared with the non-MAb-blocked well, and the neutralization rate of
the anti-HBe and unrelated antibody was used to calculated specificity.
Monoclonal antibodies. Monoclonal antibodies (MAbs) against HBV HBc or
Hbe antigens were prepared using hybridoma technology. MAbs were purified
using ammonium sulfate precipitation, followed by Mabselect Xtral affinity chro-
matography (Amersham GE Health, Uppsala, Sweden) from the ascites col-
lected. Immunoglobulin concentrations were determined by spectrophotometry
using a DU800 spectrometer (Beckman, CA). Commercial competitive anti-HBc
and anti-HBe assays (Wantai, Beijing, China) were used to analyze the reactivity
of all MAbs tested at a concentration of 50 g/ml. Two MAbs (16D5 and 8D1)
were specific anti-HBc antibodies that were reactive in the anti-HBc assay but
nonreactive in the anti-HBe assay. Three MAbs, 20B11, 11E7, and 10D8, were
found to be specific for anti-HBe and nonreactive in the anti-HBc assay. Five
other MAbs, 11H4, 18B6, 19A6, 11H10, and 4B8, showed reactivity in both
anti-HBe and anti-HBc assays.
Patient serum samples. One hundred twenty symptomatic HBV carriers
(HBsAg-positive individuals with persistent elevation of alanine aminotransferase
(ALT) levels (1.5 times the upper limit of normal for at least 3 months), 245
asymptomatic HBV carriers (HBsAg-positive individuals with a normal ALT
level and without a history of hepatitis), and 783 healthy individuals’ serum
samples (control cohort) were used to evaluate the concordance between the
sandwich ELISA method and the Architect anti-HBc CMIA. All samples were
collected from Quanzhou 1st Hospital (Quanzhou, Fujian, China), Xiamen
Blood Centre (Xiamen, Fujian, China), and Xiamen CDC (Xiamen, Fujian,
China).
HBV infectious markers. HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc
assays were performed using Architect i2000SR CMIA (Abbott Laboratories,
Abbott Park, IL). HBsAg low titer (2 IU on Architect HBsAg) samples were
confirmed by other three HBsAg assays: the Monolisa HBsAg Ultra (Bio-Rad,
Marnes La Coquette, France), the Hepanostika HBsAg Ultra (bioMe´rieux,
Marcy l’Etoile, France), and the Murex V3 ELISA (Abbott Murex, Dartford,
United Kingdom).
RESULTS
Characterization of the rHBcAg. The CpC and CpD full-
length rHBcAg were solubly expressed with high expression
levels obtained (approximately 20% in total proteins) (Fig. 1A,
lanes 1 and 2) in the BL21(DE3) cell line. The purified CpC
and CpD proteins by ion-exchange chromatography and hy-
drophobic chromatography showed single bands on SDS-
PAGE with an estimated molecular mass of about 22 kDa,
respectively (Fig. 1A, lanes 3 and 4). The high purity of HBcAg
proteins excluded the underlying interference against the im-
munoassay. Western blot analyses showed that both CpC and
CpD reacted well with anti-HBc MAb (Fig. 1B), suggesting
that the purified fractions were targets. After the in vitro capsid
assembly, the rHBcAg formed as a homogeneous particulate
structure similar in appearance to the regular 20-hedron
structure of native HBcAg particle with a 27-nm diameter
(Fig. 2A to D).
Discrimination of the sandwich ELISA between anti-HBc
and anti-HBe MAbs. The MAbs were tested by the sandwich
ELISA in serial dilution, and the reactivity titer that allowed
for a reaction to occur for each MAb was calculated (Fig. 3).
The 2 anti-HBc specific MAbs, 16D5 and 8D1, both at a con-
centration of 100 g/ml had the highest reactivity (titer,625),
whereas the 3 anti-HBe-specific MAbs 20B11, 10D8, and 11E7
presented virtually no reactivity in the sandwich assay even for
samples with a concentration higher than 100 g/ml (titer,1).
A weak reactivity of the 5 cross-HBc/Hbe MAbs was also
observed in the sandwich assay; however, this was observed
only when antibodies at a concentration of 20 to 100 g/ml
were used (5 titer 1).
Comparison of the analytical sensitivity for detecting anti-
HBc between the sandwich ELISA and Architect CMIA. Three
anti-HBc-positive sera were serially diluted in anti-HBc/anti-
HBs/HBsAg-negative serum and were detected by the sand-
wich ELISA and Architect anti-HBc CMIA in parallel (Fig. 4).
The analytical sensitivity for detecting anti-HBc of the sand-
wich ELISA is between 2- and 4-fold higher than that of the
Architect anti-HBc CMIA. While a 2- to 4-fold difference is
not considered significant in serological titers, the difference
was consistently unidirectional.
FIG. 1. SDS-PAGE (A) and Western blot (B) analysis of CpC and
CpD. (A) Purity of CpC and CpD. The concentration of separating gel
was 13.5%, and proteins were visualized by Coomassie brilliant blue
staining. Lanes 1 and 2 show the CpC- and CpD-positive fractions,
respectively, after the sonication step. Lanes 3 and 4 show the purified
CpC and CpD, respectively, by ion-exchange chromatography and
hydrophobic chromatography. (B) Immunological characterization of
purified CpC and CpD. Lanes 5 and 6 indicate the single bands of CpC
and CpD, respectively (molecular mass, 22 kDa), identified by the
monoclonal anti-HBc antibody. Lanes M, molecular mass marker
lanes.
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Concordance between the sandwich ELISA and Architect
CMIA in detecting samples in different clinical status. The
anti-HBc status of serum samples was measured by the sand-
wich ELISA and Architect anti-HBc CMIA in parallel, and the
concordance between the sandwich ELISA and Architect anti-
HBc CMIA was calculated and is shown in Table 1. Of the 120
samples of HBV patients, all were positive in both the sand-
wich ELISA and Architect anti-HBc CMIA. Among 245
asymptomatic HBV carriers, 241 specimens were positive in
the sandwich ELISA and Architect anti-HBc CMIA. The dis-
crepancy lay with 1 positive sample (a1) in the sandwich
ELISA, and the other three samples tested negative by both
assays. Thus, the concordance between the 2 tests was 99.6%
(95% confidence interval [CI], 97.8 to 99.9%). For the 783
samples from the control cohort, there were 462 positive cases
and 293 negative cases with 28 discordant results, which in-
clude 24 sandwich-positive but Architect anti-HBc-negative
and 4 Architect anti-HBc-positive but sandwich ELISA-nega-
tive cases. In reviewing the results for the total of 1,148 spec-
FIG. 2. Transmission electron microscopy of the purified HBV
core capsids: CpC (A and C) and CpD (B and D) particles. The scale
is 100 nm for panels A and B and 200 nm for panels C and D.
FIG. 3. Reactivity of different MAbs in the anti-HBc sandwich
ELISA. The primary concentrations of all MAbs were adjusted to 100
g/ml, which was then followed by 5-fold serial dilution. The y axis
shows the log5 reactivity titer. The black bar to the left highlights the
two anti-HBc-specific MAbs (16D5 and 8D1). Results for the 3 anti-
HBe specific MAbs (11E7, 10D8, and 8D1) would be represented in
the center; however, the actual reactivities cannot be seen because the
levels are too low. The gray box to the right represents the five cross-
anti-HBc/anti-HBe MAbs (11H4, 18B6, 19A6, 11H10, and 4B8).
FIG. 4. Comparison between the sandwich ELISA and Architect
anti-HBc CMIA. The broken horizontal line indicates the cutoff value.
TABLE 1. Concordance of Architect CMIA and sandwich ELISA
anti-HBc levels in HBV detection in serum samples related to
different clinical statuses
Group and status (n)
No. of samples
with result by
Architect
CMIA
% Concordance
(95% CI)
 
Hepatitis B patients (120) 100 (97.0100)
Sandwich anti-HBc 120 0
Sandwich anti-HBc 0 0
Asymptomatic carriers (245) 99.6 (97.899.9)
Sandwich anti-HBc 241 1a
Sandwich anti-HBc 0 3
Common populations (783) 96.4 (94.997.6)
Sandwich anti-HBc 462 24a
Sandwich anti-HBc 4a 293
Total (1,148) 97.8 (96.498.3)
Sandwich anti-HBc 823 25
Sandwich anti-HBc 4 296
a A total of 29 discordant samples were further analyzed by a neutralization
confirmatory assay. Finally, 28 samples (a1, b1 to b24, c1 and c2, and c4) were
found to be anti-HBc positive.
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imens tested, the concordance between sandwich ELISA and
Architect anti-HBc CMIA was 97.8% (95% CI, 96.4 to 98.3)
and there were a total of 29 discordant results. The signal/
cutoff (SCO) value correlation for all samples in the two assays
is shown in Fig. 5A. The correlation coefficient was 0.88, and
the adjusted R2 	 0.78. The SCO level of the sandwich ELISA
in 823 concordant positive samples was statistically significantly
higher than that of the Architect anti-HBc CMIA and statis-
tically significantly lower than that of the Architect anti-HBc
CMIA in the 296 concordant negative samples (Fig. 5B and C).
Analysis for the discordant samples between the sandwich
ELISA and Architect CMIA. One asymptomatic HBV carrier
(a1) and 28 (b1 to b24 and c1 to c4) in the control cohort had
discordant anti-HBc result in the two assays. All samples with
discordant anti-HBc results were tested by neutralization assay
to determine their specificity. As the graph in Fig. 6 shows, all
25 sandwich and Architect samples and 3 Architect and
sandwich samples were positive in the confirmatory assay,
except 1 (c3) Architect and sandwich sample. Otherwise,
the a1 sample was HBsAg and HBV DNA positive and with
undetectable anti-HBs, anti-HBeAg, and anti-HBe antibodies,
suggesting that the individual is at the early stage of HBV
infection. Among the other 24 (b1 to b24) sandwich and
Architect and 4 (c1 to c4) Architect and sandwich samples
from common populations, 22 samples and 1 sample, respec-
tively, were anti-HBs positive. Thus, among the total of 1,148
samples, there were 851 anti-HBc-positive and 297 anti-HBc-
negative cases. The sensitivity and specificity for the Sandwich
ELISA were 99.7% (95% CI, 99.0 to99.9%) and 100% (95%
CI, 98.8 to100%); those for the Architect CMIA were 97.1%
(95% CI, 95.7 to 98.1%) and 99.7% (95% CI, 98.1 to
99.9%), respectively.
DISCUSSION
In this technique, the production of homogenous and stable
HBcAg particles is critical. Purified monomer HBcAg proteins
are subunits for making capsids. Although numerous studies
have demonstrated that the production of truncated version of
HBcAg that mimic the sequence of HBeAg in E. coli can be
accomplished easily in terms of yield and purification (27, 28),
nevertheless, the interdimer disulfide bridges that are formed
by the Cys-183 at the C terminus of between HBcAg dimers
increased the stability of HBc capsids (14, 15). The expression
of full-length HBcAg was difficult since it has an arginine-rich
C terminus that was coded for by rare codons in E. coli. This
problem was resolved by optimizing certain codons in this
region. Since HBcAg expressed in E. coli spontaneously accu-
mulates in a particulate state - HBcAg capsids, under such
denaturing conditions, HBcAg capsids might dissolve into sub-
units, which were rinsed during purification and then assem-
bled into homogenous and stable particles. In contrast with
routine method, the presented procedure yielded proportion-
ately more particles (more than 95%; data not shown) and
better homogeneity. The novel immunoassay for anti-HBc
measurement using a sandwich ELISA method was built
around such particles. Compared with Abbott Architect CMIA
anti-HBc assay, the new sandwich ELISA has improved sensi-
tivity and specificity.
The clinical significance of using anti-HBc lies in several
clinical situations. HBV reactivation has been reported during
cancer chemotherapy, during HIV infection, and after kidney
and bone marrow transplantation (5, 7, 20, 22). There are at
least 2 reported cases of HBV reactivation with liver inflam-
mation after rituximab administration, and one patient died
FIG. 5. (A) Correlation between the Architect CMIA and sandwich ELISA in detection of anti-HBc from 1,148 samples. The y axis represents
the SCO values measured by the Architect CMIA, and the x axis represents those measured by the sandwich ELISA. The broken lines indicate
the lowest detection limit for each assay. (B) Comparison of SCO values between the sandwich ELISA and Architect anti-HBc CMIA in 823
concordant positive specimens; (C) comparison of SCO values between the Architect CMIA and the sandwich ELISA in detecting 296 concordant
negative specimens.
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from liver failure (3); the other reactivation occurred in a
patient with preexisting anti-HBs and anti-HBc antibodies (4).
When a patient is diagnosed to be reactive for “anti-HBc
alone,” several explanations might apply to this phenomenon.
First, a certain proportion of “anti-HBc-alone” individuals will
be false positive, depending both on the anti-HBc test used and
the HBV prevalence of the population investigated. Using the
sandwich ELISA should reduce this concern significantly be-
cause of its sensitivity and specificity profile. Second, “anti-
HBc-alone” individuals may be in the window phase of an
acute HBV infection when HBsAg disappears followed by
anti-HBs a few weeks later. The significance of “anti-HBc-
alone” individuals in this window period is that such individu-
als are probably infectious. Third, the status “anti-HBc alone”
can reflect an HBV infection which was resolved many years or
decades earlier. Fourth, a large fraction of “anti-HBc-alone”
patients can be assumed to have an unresolved chronic infec-
tion with low-grade, possibly intermittent virus production.
Such individuals may have detectable serum HBV DNA
(8.1%) and are potentially infectious (13). The negative
HBsAg assay is unclear in these cases, but this result can be
caused by very low concentrations of HBsAg, fixation of
HBsAg in immune complexes, or by HBsAg mutations (11,
26). From a practical point of view, there seems to be no
clear-cut distinction between “late immunity” and “unresolved
infection.” Indeed, in a study of 5,511 blood donor samples
from 3 hospitals showed that 203 (3.7%) of randomly selected
blood donors were confirmed as “anti-HBc alone.” Of these,
11 (5.4%) were HBV-DNA positive, as detected by nested
PCR. All samples had HBV-DNA levels below 400 copies/ml,
and all were genotype D. Thus, HBV was present but below
the detectable limit for the assay used. Hence, routine screen-
ing for anti-HBc may be required as an additional preventive
measure for controlling transmission of HBV via blood trans-
fusion (8). Fifth, “anti-HBc alone” may represent the suppres-
sion of HBV replication by HCV coinfection. Knoll et al. (13)
showed that in 112/550 “anti-HBc alone” individuals (20.4%)
were coinfected with HCV, and patients with HCV coinfection
more often had an elevated ALT activity or chronic liver dam-
age. The detrimental effect of HCV coinfection has previously
been reported in HBsAg-positive patients with chronic HBV
infection (6, 9). Finally, in a study of 379 samples with detect-
able anti-HBc, 155 (40.9%) were “anti-HBc only.” HBV DNA
was detected in 6/151 (4%), all of which had a viral load of
400 copies per ml. Anti-HIV was found in 50/151 (33.1%)
and anti-HCV in 14/151 (9.3%) patients. Only one of the
HIV-infected patients had detectable HBV DNA. Phyloge-
netic analysis of the HBV surface gene from three patients
showed a variety of genotypes (A, E, and G). One sequence
had a mutation in codon 144, which has previously been re-
ported to give false-negative HBsAg results. Thus, “anti-HBc
only” is a common phenomenon in the clinical virology labo-
ratory, but only a small proportion of samples had detectable
HBV DNA. The presence of HBsAg mutants with a possible
false-negative HBsAg test result is of concern. Samples with
the result “anti-HBc only” could be used to monitor the emer-
gence of these mutants (1). The assay presented here should
assist with the resolution of diagnostic difficulties with HBV.
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